Lifeward (NASDAQ:LFWD) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Lifeward (NASDAQ:LFWD) released its quarterly earnings results on Friday. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.07), FiscalAI reports. Lifeward had a negative return on equity of 243.14% and a negative net margin of 123.66%.The company had revenue of $6.62 million during the quarter, compared to analysts’ expectations of $6.53 million.

Lifeward Trading Down 5.6%

NASDAQ:LFWD traded down $0.44 during midday trading on Friday, hitting $7.45. The stock had a trading volume of 16,937 shares, compared to its average volume of 6,192. The stock has a 50-day moving average of $7.43 and a 200 day moving average of $6.99. The company has a market capitalization of $21.08 million, a price-to-earnings ratio of -0.38 and a beta of 0.38. Lifeward has a one year low of $4.14 and a one year high of $10.56. The company has a quick ratio of 1.82, a current ratio of 2.40 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Lifeward

Hedge funds and other institutional investors have recently made changes to their positions in the company. HRT Financial LP lifted its stake in Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after acquiring an additional 29,423 shares during the period. Virtu Financial LLC boosted its stake in shares of Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after purchasing an additional 37,037 shares in the last quarter. Jane Street Group LLC raised its position in shares of Lifeward by 77.3% in the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after acquiring an additional 29,927 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after purchasing an additional 198,406 shares in the last quarter. Institutional investors own 26.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LFWD. Zacks Research upgraded Lifeward from a “strong sell” rating to a “hold” rating in a research report on Monday, July 27th. Weiss Ratings upgraded shares of Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.